Clinical Trials Directory

Trials / Completed

CompletedNCT01378520

Effect of Ketoconazole on Breathlessness

The Effect of Ketoconazole on Breathlessness During Resistive Load Breathing in Patients With Chronic Obstructive Pulmonary Disease

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
20 (actual)
Sponsor
Dartmouth-Hitchcock Medical Center · Academic / Other
Sex
All
Age
50 Years
Healthy volunteers
Not accepted

Summary

Beta-endorphins, which are naturally occurring narcotic substances, have been shown to alter the perception of breathlessness. Oral ketoconazole, an antifungal antibiotic, increases blood levels of beta-endorphins. The study hypothesis is that oral ketoconazole will reduce ratings of breathlessness induced by resistive breathing loads.

Detailed description

Beta-endorphins are naturally occurring narcotic substances (like morphine) that are released by the brain under stressful conditions, such as exercise and when breathing through a resistive load (a tube containing fine wire mesh). In one study of 8 patients with coronary artery disease, ketoconazole, an oral medication used to treat fungal infections, was administered (1,200 mg at 12 midnight and 600 mg at 6 am) and increased blood levels of beta-endorphins five fold. In a recent study performed at Dartmouth-Hitchcock Medical Center, we found that ketoconazole increased blood levels of beta-endorphins in all eight patients with chronic obstructive pulmonary disease (COPD). Mean values increased by 2.5 times at four hours compared with baseline values (p = 0.0078). Based on this significant response, we propose to study the effect of ketoconazole on patients' perception of breathlessness induced by resistive breathing loads in a randomized clinical trial. The hypothesis of the study is that ketoconazole will reduce ratings of breathlessness as mediated by the increased levels of beta-endorphins.

Conditions

Interventions

TypeNameDescription
DRUGketoconazole600 mg capsule oral once
DRUGinert powderoral once

Timeline

Start date
2011-06-01
Primary completion
2012-02-01
Completion
2012-02-01
First posted
2011-06-22
Last updated
2018-06-01
Results posted
2013-11-14

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT01378520. Inclusion in this directory is not an endorsement.